News Details

Oct 17, 2023
BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinoma    read more...
Oct 17, 2023
BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)    read more...
Oct 16, 2023
BeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assets    read more...
Oct 13, 2023
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma    read more...
Sep 19, 2023
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®    read more...
Sep 19, 2023
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)    read more...
Aug 31, 2023
BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference    read more...
Aug 02, 2023
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results    read more...
Jul 21, 2023
BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC    read more...
Jul 12, 2023
BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication    read more...
Jul 10, 2023
BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors    read more...
Jul 07, 2023
BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023    read more...
Jun 15, 2023
BeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics    read more...
Jun 15, 2023
BeiGene Highlights Significant BRUKINSA® (zanubrutinib) Data at the 17th International Conference on Malignant Lymphoma    read more...
Jun 09, 2023
BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress    read more...
May 30, 2023
BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia    read more...
May 25, 2023
BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio    read more...
May 24, 2023
BeiGene to Present at Upcoming Investor Conferences    read more...
May 17, 2023
The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries    read more...
May 06, 2023
BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China    read more...